Neurodevelopmental disorder with hypotonia and brain abnormalities Cell Models for Research

Neurodevelopmental disorder with hypotonia and brain abnormalities (NDHBA) is a rare genetic condition characterized by severe hypotonia, intellectual disability, and structural brain anomalies. The exact prevalence is unknown, but it is considered ultra-rare. According to the World Health Organization (WHO), neurodevelopmental disorders affect approximately 5-10% of children globally, with genetic causes contributing significantly. The clinical impact is profound, with affected individuals requiring lifelong care. Early diagnosis and intervention are critical, but the rarity of NDHBA limits large-scale epidemiological data. The National Cancer Institute (NCI) does not track this disorder as it is not a cancer, but genetic databases like ClinVar and OMIM provide case reports and variant information. The 5-year survival is not typically reported for this condition, as it is not a malignancy, but mortality can be high in severe cases due to respiratory complications.

NDHBA is an ideal model for studying neurodevelopmental processes, synaptic function, and brain development. The disorder is often caused by mutations in genes involved in neuronal migration, synaptogenesis, and myelination. Research on NDHBA can provide insights into basic neurobiology and potential therapeutic targets. Public datasets, such as those from the Genotype-Tissue Expression (GTEx) project and the Human Brain Transcriptome, offer gene expression data across brain regions and developmental stages. Open questions include the precise molecular mechanisms linking genetic mutations to clinical phenotypes, the role of specific cell types, and the potential for targeted interventions. Gene-edited cell models are essential for functional validation of candidate variants and for drug screening.

Although NDHBA is not a cancer, the underlying pathways are critical for neurodevelopment. Key pathways include:

• • Neuronal migration: Mutations in genes like DCX, LIS1, and RELN disrupt the migration of neurons to their correct positions, leading to brain malformations.
• • Synaptic signaling: Genes such as SYNGAP1 and SHANK3 are involved in synaptic function and plasticity; their disruption leads to intellectual disability and hypotonia.
• • Myelination: Genes like PLP1 and MBP are essential for myelin formation; defects cause white matter abnormalities.
• • Transcriptional regulation: Mutations in transcription factors like FOXG1 and MEF2C affect gene expression programs critical for brain development.

Data from ClinVar and COSMIC (for somatic mutations, though NDHBA is germline).

The deregulated networks in NDHBA include:

• • RAS/MAPK pathway: Critical for synaptic plasticity and neuronal survival. Mutations in SYNGAP1 and other genes disrupt this pathway.
• • PI3K/AKT/mTOR pathway: Involved in neuronal growth and survival. Dysregulation leads to abnormal brain size and connectivity.
• • Wnt signaling: Essential for neuronal migration and cortical development. Aberrant Wnt signaling is linked to malformations.
• • Notch signaling: Regulates neural stem cell maintenance and differentiation. Mutations in Notch pathway genes cause brain abnormalities.

Key nodes: SYNGAP1, MEF2C, FOXG1, KIF1A, STXBP1, and others.

Organoids: Brain organoids derived from induced pluripotent stem cells (iPSCs) recapitulate early brain development and are valuable for studying NDHBA. They can be generated from patient-derived iPSCs and edited with CRISPR to model specific mutations.

Animal models for NDHBA include:

• • Genetically engineered mouse models (GEMMs): Knockout or knock-in mice for genes like Syngap1, Mef2c, Foxg1, and Kif1a. These mice exhibit phenotypes resembling NDHBA, such as hypotonia, seizures, and brain abnormalities.
• • Induced models: Chemical or viral-induced models to mimic specific aspects of the disease.
• • Patient-derived xenografts (PDX) are not applicable for NDHBA as it is not a cancer, but patient-derived iPSC-derived neurons can be transplanted into mice for in vivo studies.

CRISPR-based isogenic cell lines are powerful tools for studying NDHBA. By introducing specific mutations into a reference cell line (e.g., SH-SY5Y or iPSC-derived neural stem cells), researchers can create isogenic pairs that differ only in the gene of interest. For example:

• • A SYNGAP1 knockout line can be used to study the effects of loss of function on synaptic signaling.
• • A MEF2C haploinsufficient line can model the reduced gene dosage.
• • A KIF1A missense mutation knock-in line can mimic the pathogenic variant.

These models are commercially available from various sources, ensuring sequence-verified and quality-controlled cells. They accelerate research by providing reproducible and consistent models for drug screening and mechanistic studies.

Gene-edited cell lines are essential for functional validation of candidate genes identified in patient cohorts. For example, knocking out SYNGAP1 in SH-SY5Y cells can confirm its role in synaptic function. Similarly, introducing a pathogenic variant into a wild-type line can establish causality. These models allow for high-throughput screening of genetic interactions and pathway mapping.

Isogenic cell line pairs are ideal for drug screening. For instance, a SYNGAP1 knockout line can be used to screen for compounds that rescue synaptic deficits. Resistance modeling is less relevant for NDHBA, but for cancer-related neurodevelopmental disorders, such as those with PTEN mutations, drug resistance can be studied. Gene-edited lines enable the identification of drug targets and the evaluation of therapeutic efficacy.

CRISPR-based synthetic lethality screens can identify genes that, when silenced, are lethal in the context of a specific mutation. For NDHBA, this approach can uncover novel therapeutic targets. Additionally, gene-edited lines can be used to identify biomarkers for disease progression or treatment response by analyzing secreted proteins or gene expression signatures.